Global Age-Related Macular Degeneration (AMD) Treatment Drugs Supply, Demand and Key Producers, 2024-2030
Page: 122
Published Date: 22 Apr 2024
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, a part of the retina responsible for central vision. The cells in the macula become damaged and begin to die, causing vision loss as a person ages. The disease is typically categorized into two types: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common and involves the formation of small, yellow deposits in the macula, while wet AMD is less common and involves the growth of abnormal blood vessels beneath the macula. In dry AMD, treatment options include vitamin supplements and lifestyle changes to reduce risk factors. In wet AMD, treatment involves medications that are injected into the eye to stop the growth of abnormal blood vessels. This treatment is called abnormal endothelial growth factor (anti-VEGF) therapy, and it works by blocking the protein that stimulates the growth of abnormal blood vessels.
The global Age-Related Macular Degeneration (AMD) Treatment Drugs market size is expected to reach $ 15260 million by 2030, rising at a market growth of 5.6% CAGR during the forecast period (2024-2030).
The age-related macular degeneration (AMD) market trends are shaping the growth of the market. For instance rise in the adoption of age-related macular degeneration drugs (AMD) among the geriatric population suffering from age-related macular degeneration (AMD) drives the growth of the age-related macular degeneration (AMD) market size. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, indicating a potential increase in the age-related macular degeneration (AMD) market size.
This report studies the global Age-Related Macular Degeneration (AMD) Treatment Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Age-Related Macular Degeneration (AMD) Treatment Drugs and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Age-Related Macular Degeneration (AMD) Treatment Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Age-Related Macular Degeneration (AMD) Treatment Drugs total production and demand, 2019-2030, (K Dose)
Global Age-Related Macular Degeneration (AMD) Treatment Drugs total production value, 2019-2030, (USD Million)
Global Age-Related Macular Degeneration (AMD) Treatment Drugs production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Dose), (based on production site)
Global Age-Related Macular Degeneration (AMD) Treatment Drugs consumption by region & country, CAGR, 2019-2030 & (K Dose)
U.S. VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs domestic production, consumption, key domestic manufacturers and share
Global Age-Related Macular Degeneration (AMD) Treatment Drugs production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Dose)
Global Age-Related Macular Degeneration (AMD) Treatment Drugs production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Dose)
Global Age-Related Macular Degeneration (AMD) Treatment Drugs production by Application, production, value, CAGR, 2019-2030, (USD Million) & (K Dose)
This report profiles key players in the global Age-Related Macular Degeneration (AMD) Treatment Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ionis Pharmaceuticals, Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc, Biogen, Novartis AG, Sanofi S.A., Bayer AG, Coherus Biosciences Inc, F. Hoffmann-La Roche Ltd, Apellis Pharmaceuticals Inc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Age-Related Macular Degeneration (AMD) Treatment Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.
Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market, Segmentation by Type:
Aflibercept
Ranibizumab
Others
Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market, Segmentation by Application:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Companies Profiled:
Ionis Pharmaceuticals, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Biogen
Novartis AG
Sanofi S.A.
Bayer AG
Coherus Biosciences Inc
F. Hoffmann-La Roche Ltd
Apellis Pharmaceuticals Inc
AbbVie
Pfizer Inc.
Amgen Inc.
Samsung Bioepis
Key Questions Answered:
1. How big is the global Age-Related Macular Degeneration (AMD) Treatment Drugs market?
2. What is the demand of the global Age-Related Macular Degeneration (AMD) Treatment Drugs market?
3. What is the year over year growth of the global Age-Related Macular Degeneration (AMD) Treatment Drugs market?
4. What is the production and production value of the global Age-Related Macular Degeneration (AMD) Treatment Drugs market?
5. Who are the key producers in the global Age-Related Macular Degeneration (AMD) Treatment Drugs market?
6. What are the growth factors driving the market demand?
Table of Contents
1 Supply Summary
1.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Introduction
1.2 World Age-Related Macular Degeneration (AMD) Treatment Drugs Supply & Forecast
1.2.1 World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value (2019 & 2023 & 2030)
1.2.2 World Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2030)
1.2.3 World Age-Related Macular Degeneration (AMD) Treatment Drugs Pricing Trends (2019-2030)
1.3 World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Region (Based on Production Site)
1.3.1 World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Region (2019-2030)
1.3.2 World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Region (2019-2030)
1.3.3 World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Region (2019-2030)
1.3.4 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2030)
1.3.5 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2030)
1.3.6 China Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2030)
1.3.7 Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2030)
1.4 Market Drivers, Restraints and Trends
1.4.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Major Market Trends
2.1 World Age-Related Macular Degeneration (AMD) Treatment Drugs Demand (2019-2030)
2.2 World Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption by Region
2.2.1 World Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption by Region (2019-2024)
2.2.2 World Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Forecast by Region (2025-2030)
2.3 United States Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030)
2.4 China Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030)
2.5 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030)
2.6 Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030)
2.7 South Korea Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030)
2.8 ASEAN Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030)
2.9 India Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030)
3.1 World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Manufacturer (2019-2024)
3.2 World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Manufacturer (2019-2024)
3.3 World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Manufacturer (2019-2024)
3.4 Age-Related Macular Degeneration (AMD) Treatment Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Age-Related Macular Degeneration (AMD) Treatment Drugs in 2023
3.5.3 Global Concentration Ratios (CR8) for Age-Related Macular Degeneration (AMD) Treatment Drugs in 2023
3.6 Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Overall Company Footprint Analysis
3.6.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Region Footprint
3.6.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Company Product Type Footprint
3.6.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4.1 United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Comparison
4.1.1 United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Comparison (2019 & 2023 & 2030)
4.1.2 United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share Comparison (2019 & 2023 & 2030)
4.2 United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Production Comparison
4.2.1 United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Production Comparison (2019 & 2023 & 2030)
4.2.2 United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share Comparison (2019 & 2023 & 2030)
4.3 United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Comparison
4.3.1 United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Comparison (2019 & 2023 & 2030)
4.3.2 United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Market Share Comparison (2019 & 2023 & 2030)
4.4 United States Based Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturers and Market Share, 2019-2024
4.4.1 United States Based Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value (2019-2024)
4.4.3 United States Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2024)
4.5 China Based Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturers and Market Share
4.5.1 China Based Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value (2019-2024)
4.5.3 China Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2024)
4.6 Rest of World Based Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturers and Market Share, 2019-2024
4.6.1 Rest of World Based Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value (2019-2024)
4.6.3 Rest of World Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2024)
5.1 World Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Overview by Type: 2019 VS 2023 VS 2030
5.2 Segment Introduction by Type
5.2.1 Aflibercept
5.2.2 Ranibizumab
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Type (2019-2030)
5.3.2 World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Type (2019-2030)
5.3.3 World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Type (2019-2030)
6.1 World Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Overview by Application: 2019 VS 2023 VS 2030
6.2 Segment Introduction by Application
6.2.1 Hospital Pharmacy
6.2.2 Retail Pharmacy
6.2.3 Online Pharmacy
6.3 Market Segment by Application
6.3.1 World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Application (2019-2030)
6.3.2 World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Application (2019-2030)
6.3.3 World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Application (2019-2030)
7.1 Ionis Pharmaceuticals, Inc
7.1.1 Ionis Pharmaceuticals, Inc Details
7.1.2 Ionis Pharmaceuticals, Inc Major Business
7.1.3 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.1.4 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.1.5 Ionis Pharmaceuticals, Inc Recent Developments/Updates
7.1.6 Ionis Pharmaceuticals, Inc Competitive Strengths & Weaknesses
7.2 Bausch Health Companies Inc
7.2.1 Bausch Health Companies Inc Details
7.2.2 Bausch Health Companies Inc Major Business
7.2.3 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.2.4 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.2.5 Bausch Health Companies Inc Recent Developments/Updates
7.2.6 Bausch Health Companies Inc Competitive Strengths & Weaknesses
7.3 Regeneron Pharmaceuticals Inc
7.3.1 Regeneron Pharmaceuticals Inc Details
7.3.2 Regeneron Pharmaceuticals Inc Major Business
7.3.3 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.3.4 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.3.5 Regeneron Pharmaceuticals Inc Recent Developments/Updates
7.3.6 Regeneron Pharmaceuticals Inc Competitive Strengths & Weaknesses
7.4 Biogen
7.4.1 Biogen Details
7.4.2 Biogen Major Business
7.4.3 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.4.4 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.4.5 Biogen Recent Developments/Updates
7.4.6 Biogen Competitive Strengths & Weaknesses
7.5 Novartis AG
7.5.1 Novartis AG Details
7.5.2 Novartis AG Major Business
7.5.3 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.5.4 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.5.5 Novartis AG Recent Developments/Updates
7.5.6 Novartis AG Competitive Strengths & Weaknesses
7.6 Sanofi S.A.
7.6.1 Sanofi S.A. Details
7.6.2 Sanofi S.A. Major Business
7.6.3 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.6.4 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.6.5 Sanofi S.A. Recent Developments/Updates
7.6.6 Sanofi S.A. Competitive Strengths & Weaknesses
7.7 Bayer AG
7.7.1 Bayer AG Details
7.7.2 Bayer AG Major Business
7.7.3 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.7.4 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.7.5 Bayer AG Recent Developments/Updates
7.7.6 Bayer AG Competitive Strengths & Weaknesses
7.8 Coherus Biosciences Inc
7.8.1 Coherus Biosciences Inc Details
7.8.2 Coherus Biosciences Inc Major Business
7.8.3 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.8.4 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.8.5 Coherus Biosciences Inc Recent Developments/Updates
7.8.6 Coherus Biosciences Inc Competitive Strengths & Weaknesses
7.9 F. Hoffmann-La Roche Ltd
7.9.1 F. Hoffmann-La Roche Ltd Details
7.9.2 F. Hoffmann-La Roche Ltd Major Business
7.9.3 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.9.4 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.9.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
7.9.6 F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
7.10 Apellis Pharmaceuticals Inc
7.10.1 Apellis Pharmaceuticals Inc Details
7.10.2 Apellis Pharmaceuticals Inc Major Business
7.10.3 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.10.4 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.10.5 Apellis Pharmaceuticals Inc Recent Developments/Updates
7.10.6 Apellis Pharmaceuticals Inc Competitive Strengths & Weaknesses
7.11 AbbVie
7.11.1 AbbVie Details
7.11.2 AbbVie Major Business
7.11.3 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.11.4 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.11.5 AbbVie Recent Developments/Updates
7.11.6 AbbVie Competitive Strengths & Weaknesses
7.12 Pfizer Inc.
7.12.1 Pfizer Inc. Details
7.12.2 Pfizer Inc. Major Business
7.12.3 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.12.4 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.12.5 Pfizer Inc. Recent Developments/Updates
7.12.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.13 Amgen Inc.
7.13.1 Amgen Inc. Details
7.13.2 Amgen Inc. Major Business
7.13.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.13.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.13.5 Amgen Inc. Recent Developments/Updates
7.13.6 Amgen Inc. Competitive Strengths & Weaknesses
7.14 Samsung Bioepis
7.14.1 Samsung Bioepis Details
7.14.2 Samsung Bioepis Major Business
7.14.3 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
7.14.4 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.14.5 Samsung Bioepis Recent Developments/Updates
7.14.6 Samsung Bioepis Competitive Strengths & Weaknesses
8.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Chain
8.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Upstream Analysis
8.2.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Core Raw Materials
8.2.2 Main Manufacturers of Age-Related Macular Degeneration (AMD) Treatment Drugs Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Age-Related Macular Degeneration (AMD) Treatment Drugs Production Mode
8.6 Age-Related Macular Degeneration (AMD) Treatment Drugs Procurement Model
8.7 Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Sales Model and Sales Channels
8.7.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Model
8.7.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Typical Distributors
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Region (2019, 2023 and 2030) & (USD Million)
Table 2. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Region (2019-2024) & (USD Million)
Table 3. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Region (2025-2030) & (USD Million)
Table 4. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share by Region (2019-2024)
Table 5. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share by Region (2025-2030)
Table 6. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Region (2019-2024) & (K Dose)
Table 7. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Region (2025-2030) & (K Dose)
Table 8. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share by Region (2019-2024)
Table 9. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share by Region (2025-2030)
Table 10. World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Region (2019-2024) & (US$/Dose)
Table 11. World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Region (2025-2030) & (US$/Dose)
Table 12. Age-Related Macular Degeneration (AMD) Treatment Drugs Major Market Trends
Table 13. World Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K Dose)
Table 14. World Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption by Region (2019-2024) & (K Dose)
Table 15. World Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Forecast by Region (2025-2030) & (K Dose)
Table 16. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Manufacturer (2019-2024) & (USD Million)
Table 17. Production Value Market Share of Key Age-Related Macular Degeneration (AMD) Treatment Drugs Producers in 2023
Table 18. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Manufacturer (2019-2024) & (K Dose)
Table 19. Production Market Share of Key Age-Related Macular Degeneration (AMD) Treatment Drugs Producers in 2023
Table 20. World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Manufacturer (2019-2024) & (US$/Dose)
Table 21. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Company Evaluation Quadrant
Table 22. World Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2023
Table 23. Head Office and Age-Related Macular Degeneration (AMD) Treatment Drugs Production Site of Key Manufacturer
Table 24. Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Company Product Type Footprint
Table 25. Age-Related Macular Degeneration (AMD) Treatment Drugs Market: Company Product Application Footprint
Table 26. Age-Related Macular Degeneration (AMD) Treatment Drugs Competitive Factors
Table 27. Age-Related Macular Degeneration (AMD) Treatment Drugs New Entrant and Capacity Expansion Plans
Table 28. Age-Related Macular Degeneration (AMD) Treatment Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 30. United States VS China Age-Related Macular Degeneration (AMD) Treatment Drugs Production Comparison, (2019 & 2023 & 2030) & (K Dose)
Table 31. United States VS China Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Comparison, (2019 & 2023 & 2030) & (K Dose)
Table 32. United States Based Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value, (2019-2024) & (USD Million)
Table 34. United States Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share (2019-2024)
Table 35. United States Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2024) & (K Dose)
Table 36. United States Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share (2019-2024)
Table 37. China Based Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value, (2019-2024) & (USD Million)
Table 39. China Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share (2019-2024)
Table 40. China Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production, (2019-2024) & (K Dose)
Table 41. China Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share (2019-2024)
Table 42. Rest of World Based Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value, (2019-2024) & (USD Million)
Table 44. Rest of World Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share (2019-2024)
Table 45. Rest of World Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production, (2019-2024) & (K Dose)
Table 46. Rest of World Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share (2019-2024)
Table 47. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Type, (USD Million), 2019 & 2023 & 2030
Table 48. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Type (2019-2024) & (K Dose)
Table 49. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Type (2025-2030) & (K Dose)
Table 50. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Type (2019-2024) & (USD Million)
Table 51. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Type (2025-2030) & (USD Million)
Table 52. World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Type (2019-2024) & (US$/Dose)
Table 53. World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Type (2025-2030) & (US$/Dose)
Table 54. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Application, (USD Million), 2019 & 2023 & 2030
Table 55. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Application (2019-2024) & (K Dose)
Table 56. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production by Application (2025-2030) & (K Dose)
Table 57. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Application (2019-2024) & (USD Million)
Table 58. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Application (2025-2030) & (USD Million)
Table 59. World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Application (2019-2024) & (US$/Dose)
Table 60. World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Application (2025-2030) & (US$/Dose)
Table 61. Ionis Pharmaceuticals, Inc Basic Information, Manufacturing Base and Competitors
Table 62. Ionis Pharmaceuticals, Inc Major Business
Table 63. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 64. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 65. Ionis Pharmaceuticals, Inc Recent Developments/Updates
Table 66. Ionis Pharmaceuticals, Inc Competitive Strengths & Weaknesses
Table 67. Bausch Health Companies Inc Basic Information, Manufacturing Base and Competitors
Table 68. Bausch Health Companies Inc Major Business
Table 69. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 70. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 71. Bausch Health Companies Inc Recent Developments/Updates
Table 72. Bausch Health Companies Inc Competitive Strengths & Weaknesses
Table 73. Regeneron Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 74. Regeneron Pharmaceuticals Inc Major Business
Table 75. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 76. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 77. Regeneron Pharmaceuticals Inc Recent Developments/Updates
Table 78. Regeneron Pharmaceuticals Inc Competitive Strengths & Weaknesses
Table 79. Biogen Basic Information, Manufacturing Base and Competitors
Table 80. Biogen Major Business
Table 81. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 82. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 83. Biogen Recent Developments/Updates
Table 84. Biogen Competitive Strengths & Weaknesses
Table 85. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 86. Novartis AG Major Business
Table 87. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 88. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 89. Novartis AG Recent Developments/Updates
Table 90. Novartis AG Competitive Strengths & Weaknesses
Table 91. Sanofi S.A. Basic Information, Manufacturing Base and Competitors
Table 92. Sanofi S.A. Major Business
Table 93. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 94. Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 95. Sanofi S.A. Recent Developments/Updates
Table 96. Sanofi S.A. Competitive Strengths & Weaknesses
Table 97. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 98. Bayer AG Major Business
Table 99. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 100. Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 101. Bayer AG Recent Developments/Updates
Table 102. Bayer AG Competitive Strengths & Weaknesses
Table 103. Coherus Biosciences Inc Basic Information, Manufacturing Base and Competitors
Table 104. Coherus Biosciences Inc Major Business
Table 105. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 106. Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 107. Coherus Biosciences Inc Recent Developments/Updates
Table 108. Coherus Biosciences Inc Competitive Strengths & Weaknesses
Table 109. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 110. F. Hoffmann-La Roche Ltd Major Business
Table 111. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 112. F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 113. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 114. F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses
Table 115. Apellis Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 116. Apellis Pharmaceuticals Inc Major Business
Table 117. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 118. Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 119. Apellis Pharmaceuticals Inc Recent Developments/Updates
Table 120. Apellis Pharmaceuticals Inc Competitive Strengths & Weaknesses
Table 121. AbbVie Basic Information, Manufacturing Base and Competitors
Table 122. AbbVie Major Business
Table 123. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 124. AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 125. AbbVie Recent Developments/Updates
Table 126. AbbVie Competitive Strengths & Weaknesses
Table 127. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 128. Pfizer Inc. Major Business
Table 129. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 130. Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 131. Pfizer Inc. Recent Developments/Updates
Table 132. Pfizer Inc. Competitive Strengths & Weaknesses
Table 133. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 134. Amgen Inc. Major Business
Table 135. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 136. Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 137. Amgen Inc. Recent Developments/Updates
Table 138. Amgen Inc. Competitive Strengths & Weaknesses
Table 139. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 140. Samsung Bioepis Major Business
Table 141. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product and Services
Table 142. Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 143. Samsung Bioepis Recent Developments/Updates
Table 144. Samsung Bioepis Competitive Strengths & Weaknesses
Table 145. Global Key Players of Age-Related Macular Degeneration (AMD) Treatment Drugs Upstream (Raw Materials)
Table 146. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Typical Customers
Table 147. Age-Related Macular Degeneration (AMD) Treatment Drugs Typical Distributors
List of Figures
Figure 1. Age-Related Macular Degeneration (AMD) Treatment Drugs Picture
Figure 2. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value: 2019 & 2023 & 2030, (USD Million)
Figure 3. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value and Forecast (2019-2030) & (USD Million)
Figure 4. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2030) & (K Dose)
Figure 5. World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price (2019-2030) & (US$/Dose)
Figure 6. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share by Region (2019-2030)
Figure 7. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share by Region (2019-2030)
Figure 8. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2030) & (K Dose)
Figure 9. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2030) & (K Dose)
Figure 10. China Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2030) & (K Dose)
Figure 11. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Production (2019-2030) & (K Dose)
Figure 12. Age-Related Macular Degeneration (AMD) Treatment Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030) & (K Dose)
Figure 15. World Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Market Share by Region (2019-2030)
Figure 16. United States Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030) & (K Dose)
Figure 17. China Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030) & (K Dose)
Figure 18. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030) & (K Dose)
Figure 19. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030) & (K Dose)
Figure 20. South Korea Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030) & (K Dose)
Figure 21. ASEAN Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030) & (K Dose)
Figure 22. India Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption (2019-2030) & (K Dose)
Figure 23. Producer Shipments of Age-Related Macular Degeneration (AMD) Treatment Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
Figure 24. Global Four-firm Concentration Ratios (CR4) for Age-Related Macular Degeneration (AMD) Treatment Drugs Markets in 2023
Figure 25. Global Four-firm Concentration Ratios (CR8) for Age-Related Macular Degeneration (AMD) Treatment Drugs Markets in 2023
Figure 26. United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share Comparison (2019 & 2023 & 2030)
Figure 27. United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share Comparison (2019 & 2023 & 2030)
Figure 28. United States VS China: Age-Related Macular Degeneration (AMD) Treatment Drugs Consumption Market Share Comparison (2019 & 2023 & 2030)
Figure 29. United States Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share 2023
Figure 30. China Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share 2023
Figure 31. Rest of World Based Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share 2023
Figure 32. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 33. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share by Type in 2023
Figure 34. Aflibercept
Figure 35. Ranibizumab
Figure 36. Others
Figure 37. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share by Type (2019-2030)
Figure 38. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share by Type (2019-2030)
Figure 39. World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Type (2019-2030) & (US$/Dose)
Figure 40. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 41. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share by Application in 2023
Figure 42. Hospital Pharmacy
Figure 43. Retail Pharmacy
Figure 44. Online Pharmacy
Figure 45. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share by Application (2019-2030)
Figure 46. World Age-Related Macular Degeneration (AMD) Treatment Drugs Production Value Market Share by Application (2019-2030)
Figure 47. World Age-Related Macular Degeneration (AMD) Treatment Drugs Average Price by Application (2019-2030) & (US$/Dose)
Figure 48. Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Chain
Figure 49. Age-Related Macular Degeneration (AMD) Treatment Drugs Procurement Model
Figure 50. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Model
Figure 51. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Channels, Direct Sales, and Distribution
Figure 52. Methodology
Figure 53. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Ionis Pharmaceuticals, Inc Bausch Health Companies Inc Regeneron Pharmaceuticals Inc Biogen Novartis AG Sanofi S.A. Bayer AG Coherus Biosciences Inc F. Hoffmann-La Roche Ltd Apellis Pharmaceuticals Inc AbbVie Pfizer Inc. Amgen Inc. Samsung Bioepis
22 Apr 2024
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
